- Home
- / Galena Biopharma
- / Financials
Header placeholder lorem ipsum dolor sit amet, consectetur adipiscing elit.
Galena Biopharma financials data including stock price, CreditSafe score, income statement, balance sheet, and cash flow.
Revenue
$7.6 M
FY, 2021
CreditSafe Score
?
Score changed on Jul 19, 2026
Premium Content only available in Craft’s Intelligence Portal
View 30+ financial ratio metrics including price-to-earnings ratio, debt-to-assets ratio, gross profit margin, and more.
Financial ratio metrics help evaluate the financial strength of a company, and help raise red flags that can indicate potential risk, fulfillment challenges, or even possible bankruptcy.
Learn moreFinancial Statements
| USD | FY, 2011 | FY, 2012 | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 | FY, 2020 | FY, 2021 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2.5M | 9.3M | 1.9M | 7.6M | |||||||
| Cost of goods sold | 520.0K | 1.4M | 200.0K | ||||||||
| Gross profit | 2.0M | 7.9M | |||||||||
| Gross profit margin, % | 79.1% | 84.9% | |||||||||
| General and administrative expense | 9.2M | 6.6M | 15.1M | 12.8M | 9.9M | 9.6M | 11.3M | ||||
| Operating expense total | 20.8M | 21.2M | 35.8M | 60.1M | 23.6M | 19.9M | 21.2M | 23.6M | 17.9M | 32.7M | |
| EBIT | (33.3M) | (33.8M) | (52.2M) | (34.2M) | (31.9M) | (23.0M) | (17.0M) | (25.3M) | |||
| EBIT margin, % | -1360.7% | -560.4% | |||||||||
| Interest income | 208.0K | ||||||||||
| Interest expense | 6.0K | 1.0K | 547.0K | 800.0K | 4.4M | 21.0M | 266.0K | 118.0K | 26.0K | 6.0K | |
| Pre tax profit | (11.5M) | (34.4M) | (75.6M) | (36.6M) | (38.6M) | (10.9M) | (23.5M) | (29.0M) | (19.4M) | (16.8M) | (20.9M) |
| Income tax expense | (1.1M) | 1.1M | 365.0K | 243.0K | 253.0K | (1.4M) | (81.0K) | (17.0K) | (237.0K) | ||
| Net Income | (11.5M) | (35.0M) | (76.7M) | (36.6M) | (63.9M) | (23.5M) | (23.8M) | (27.7M) | (19.3M) | (16.8M) | (20.7M) |